Sitagliptin (NCT07003542)

Name: Sitagliptin trial for Glioblastoma (NCT07003542)
Uploaded: 2026-10-31T20:16:40.902Z
Duration: 1 min 14 s
Description: Sitagliptin trial for Glioblastoma (NCT07003542). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT07003542.

A Phase 2 and Pharmacodynamic Study of Sitagliptin in Patients With Progressive Grade 4 Gliomas: a one-minute explainerNCT070035421 min

Sitagliptin trial for Glioblastoma (NCT07003542). This is a short film with English narration. The transcript is on this page, and the written brief is separate.

What the film says

Read the transcript

This trial is for people over eighteen with recurrent grade 4 glioma who have planned tumor surgery and can receive postoperative chemotherapy. Previous sitagliptin or other gliptins excludes participation.

The idea: sitagliptin blocks DPP-4, which certain immune-suppressing cells use to enter the brain. Researchers test whether this changes tumor immunity. Patients are randomized to oral sitagliptin before surgery or no presurgical drug; both groups receive sitagliptin and chemotherapy afterward. Tumor samples are compared for immune-cell differences.

This phase 2 study plans 48 patients. David Peereboom leads in Cleveland, the sole recruiting US site.

Public record; not medical advice.

Read the full brief →

Already in a trial?

It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.

Organize my trial

7-day free trial, then $9 a month. Cancel anytime.